SCYX Stock Overview
SCYNEXIS, Inc., a biotechnology company, develops products for the treatment fungal infections in the United States.
+ 2 more risks
SCYNEXIS, Inc. Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$2.12|
|52 Week High||US$7.58|
|52 Week Low||US$1.70|
|1 Month Change||17.78%|
|3 Month Change||-16.54%|
|1 Year Change||-70.35%|
|3 Year Change||-70.96%|
|5 Year Change||-90.74%|
|Change since IPO||-97.64%|
Recent News & Updates
SCYNEXIS, Inc. (NASDAQ:SCYX) Analysts Just Cut Their EPS Forecasts SubstantiallyApr 07
Some Analysts Just Cut Their SCYNEXIS, Inc. (NASDAQ:SCYX) EstimatesFeb 13
Is SCYNEXIS (NASDAQ:SCYX) Using Debt In A Risky Way?Dec 03
Is SCYNEXIS (NASDAQ:SCYX) Using Too Much Debt?Apr 13
Market Sentiment Around Loss-Making SCYNEXIS, Inc. (NASDAQ:SCYX)Mar 15
Here's What SCYNEXIS, Inc.'s (NASDAQ:SCYX) Shareholder Ownership Structure Looks LikeFeb 01
Trade Alert: The CEO, President & Director Of SCYNEXIS, Inc. (NASDAQ:SCYX), Marco Taglietti, Has Just Spent US$250k Buying 57% More SharesDec 28
SCYNEXIS, Inc. (NASDAQ:SCYX): Are Analysts Optimistic?Dec 15
|SCYX||US Pharmaceuticals||US Market|
Return vs Industry: SCYX underperformed the US Pharmaceuticals industry which returned 14.1% over the past year.
Return vs Market: SCYX underperformed the US Market which returned -19.6% over the past year.
|SCYX Average Weekly Movement||11.8%|
|Pharmaceuticals Industry Average Movement||11.1%|
|Market Average Movement||7.4%|
|10% most volatile stocks in US Market||15.5%|
|10% least volatile stocks in US Market||3.3%|
Stable Share Price: SCYX is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 12% a week.
Volatility Over Time: SCYX's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
SCYNEXIS, Inc., a biotechnology company, develops products for the treatment fungal infections in the United States. It offers BREXAFEMME (ibrexafungerp tablets) for the treatment of vulvovaginal candidiasis (VVC). The company is developing its lead product candidate, Ibrexafungerp, as a novel oral and intravenous drug for the treatment of various fungal infections, including recurrent VVC, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections; and ibrexafungerp that has completed Phase 3 CANDLE study for the prevention of recurrent (VVC).
SCYNEXIS, Inc. Fundamentals Summary
|SCYX fundamental statistics|
Is SCYX overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|SCYX income statement (TTM)|
|Cost of Revenue||US$599.00k|
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
|Earnings per share (EPS)||-2.38|
|Net Profit Margin||-1,864.15%|
How did SCYX perform over the long term?See historical performance and comparison